Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.

Elevated serum phosphorus and calcium are associated with arterial calcification and mortality in dialysis patients. Unlike calcium-based binders, sevelamer attenuates arterial calcification but it is unknown whether sevelamer affects mortality or morbidity. In a multicenter, randomized, open-label, parallel design trial we compared sevelamer and calcium-based binders on all-cause and cause-specific mortality (cardiovascular, infection, and other) in prevalent hemodialysis patients. A total of 2103 patients were initially randomized to treatment and 1068 patients completed the study. All-cause mortality rates and cause-specific mortality rates were not significantly different. There was a significant age interaction on the treatment effect. Only in patients over 65 years of age was there a significant effect of sevelamer in lowering the mortality rate. There was a suggestion that sevelamer was associated with lower overall, but not cardiovascular-linked, mortality in older patients. We suggest that further research is needed to confirm these findings.

Once-weekly epoetin alfa for treating the anemia of chronic kidney disease.

BACKGROUND AND AIM: Anemia occurs in approximately 47% of patients with chronic kidney disease (CKD) not on dialysis. Recombinant human erythropoietin (r-HuEPO, epoetin alfa) has been proven safe and effective for anemia treatment in patients with CKD using a three times-weekly regimen. The current study was conducted to evaluate the clinical safety and efficacy of a less frequent dosing regimen (once weekly) in this population. METHODS: This prospective, multicenter, open-label, non-randomized study enrolled 1,557 adult anemic (hemoglobin (Hb) < or = 10 g/dl) CKD patients not on dialysis. Epoetin alfa 10,000 U was administered subcutaneously once weekly for 16 weeks. Titration to 20,000 U once weekly at week 5 was permitted if patients had an increase in Hb < 1 g/dl. Safety and efficacy were assessed by changes in health-related quality of life (Linear Analog Scale Assessment (LASA) and Kidney Disease Questionnaire (KDQ)), changes in hematologic parameters and transfusion utilization, and incidence and severity of adverse events. RESULTS: 1,338 patients were evaluable for efficacy. Mean Hb level increased from 9.1 g/dl at baseline to 11.6 g/dl at study completion (last observed value after baseline) (p < 0.0001). Overall, 89.8% of patients responded to once-weekly dosing, exhibiting an increase in Hb level of > or = 1 g/dl from baseline. The percentage of patients that required transfusion decreased from 11.1% (baseline) to 3.7% (during the study) (p < 0.0001). All quality-of-life parameters improved significantly from baseline (p < 0.0001). Mean LASA scores for energy, activity and overall quality of life increased from baseline to study completion by 27.9 mm (70.5%), 24.5 mm (57.0%) and 22.6 mm (47.4%), respectively. All 5 KDQ domains showed statistically significant improvements (p < 0.0001). Hb change was a strong predictor for all 5 KDQ domains and the overall score (p < 0.0001). Treatment with once-weekly epoetin alfa was well tolerated, similar to that reported with three times-weekly dosing. CONCLUSION: Once-weekly epoetin alfa therapy is safe and effective for treating anemia in patients with CKD not on dialysis, and is associated with significant improvements in functional status and quality of life.

Effect of chronic peritoneal fluid eosinophilia on peritoneal membrane function.

This study was undertaken to evaluate the effects of long-term persistent peritoneal fluid eosinophilia on the peritoneal membrane as reflected by a change in dialysis function. This was a prospective study undertaken at a community-based peritoneal dialysis unit, where thirty-one patients were enrolled over a 9-month period. Chronic, long-term peritoneal fluid eosinophilia was noted in 12/31 (38.7%) patients. Significant differences were not noted between values of creatinine clearance, D/P urea and Kt/V, compared to their baseline values. This study shows that long-term peritoneal fluid eosinophilia does not significantly affect peritoneal membrane function in patients on maintenance peritoneal dialysis.

Triazolam impairs delayed recall but not acquisition of various everyday memory tasks in humans.

A double-blind test battery was administered to 24 human subjects (8 control, 16 drug) to assess the effects of 0.125 mg triazolam (oral) on memory encoding and retention across delay intervals ranging from seconds to 1 week after presentation. Although the drug reduced immediate psychomotor performance, it did not impair recall of previously learned information, nor did it significantly impair encoding of new information. The drug enhanced immediate recall of the location and identity of playing cards, without affecting 4-h delayed recall. The drug treatment impaired correct recall of object names after a delay of 20 min. At 4 h delay, the drug impaired olfactory recognition and free-recall of object names. At both 1 day and 1 week delay, the drug impaired recall of biographical information and correct identification of picture-photographer pair associations. The drug also impaired the daily improvement of the drug group as compared with the control group in a geometric puzzle solving task. The time course of these memory impairments compares well with the known effects of triazolam on long-term potentiation (LTP), a candidate biological mechanism underlying telencephalic memory formation and expression.

Acute renal toxicity after ingestion of Lava light liquid.

A 65-year-old man with a history of alcohol abuse and seizure disorder presented to the emergency department with altered mental status, increased anion gap acidosis, phenytoin toxicity, and acute kidney failure. The patient had ingested the liquid contents of a Lava light, which contained chlorinated paraffin, polyethylene glycol (molecular weight 200), kerosene, and micro-crystalline wax. Gas chromatography-mass spectrophotometry of the patient's blood produced results consistent with the same analysis of the Lava light contents. After 3 days of declining mental status and worsening kidney function, the patient required hemodialysis. After a prolonged hospitalization, the patient was discharged home with residual renal insufficiency. Although multifactorial, the associated renal toxicity was most probably related to the low molecular weight polyethylene glycol content of the lamp's liquid contents.

Use of a phosphorus-enriched dialysate in a hypercatabolic renal failure patient receiving intensive hemodialysis therapy.

An elderly man with end-stage renal disease required intensive hemodialysis therapy because of sepsis-induced hypercatabolism. We were able to prevent the occurrence of hypophosphatemia by using a phosphorus-enriched dialysate during hemodialysis treatments.

Effect of dialysate temperature on central hemodynamics and urea kinetics.

Use of cool dialysate is associated with increased intradialytic blood pressure, but the hemodynamic mechanism is unknown. Whether changes in dialysate temperature affect muscle blood flow, which may the alter the degree of urea compartmentalization, also is unknown. We measured hemodynamics and blood and dialysate-side urea kinetic indices in nine hemodialysis patients during two cool (35.0 degrees C) versus two warm (37.5 degrees C) dialysate treatments. The % change in mean arterial pressure was different when using the cool (+6.5 +/- 9.7 mm Hg) versus the warm (-13.4 +/- 3.6) dialysate (P < 0.01), despite comparable amounts of fluid removal. Percent changes in cardiac output were similar with the two dialysates, and thus the blood pressure effect was due primarily to changes in total peripheral resistance (% delta TPR, cool +26 +/- 13.6, warm +8.6 +/- 14.5; P < 0.02). During cool dialysate use tympanic membrane temperature changed by -0.51 +/- 0.23 degree C, whereas body temperature increased by 0.52 +/- 0.14 degree C during use of warm dialysate. Measured urea recovery normalized to the predialysis urea nitrogen concentration was similar with the two treatments: cool 31.3 +/- 0.039 liter-1; warm 29.7 +/- 0.021; P = NS. In a second study, post-dialysis urea rebound values from 15 seconds to 30 minutes, expressed as the percent of the post-dialysis SUN, were similar after the two treatments: cool 11.79 +/- 1.4; warm 12.21 +/- 2.27, P = NS.(ABSTRACT TRUNCATED AT 250 WORDS)

Use of a phosphorus-enriched dialysis solution to hemodialyze a patient with lithium intoxication.

A normophosphatemic patient suffering from lithium intoxication was hemodialyzed with a phosphorus-enriched, bicarbonate-based dialysis solution. A post-dialysis fall in plasma phosphorus level was prevented.

Gastrospirillum hominis in acute gastric erosion.

Gastrospirillum hominis is a spirochete that has been described in association with chronic gastritis and duodenal ulcers. We report the case of a patient having acute gastric erosion in whom biopsy showed abundant organisms. The erosion resolved while the patient was receiving sucralfate and omeprazole therapy. We discuss the histopathology and mode of transmission of G hominis, along with the role of antibiotic therapy.

Septic shock in an elderly patient: unusual presentation of echovirus infection.

We have described a case of fulminant echovirus infection that progressed rapidly to purpura and septic shock. To our knowledge, this is a previously unreported presentation of acute echovirus infection in an immunocompetent adult.